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Tamoxifen prevents recurrence after breast cancer and breast cancer among high-risk women, and may prevent myocardial infarction
(MI). To assess the impact of tamoxifen on MI risk, we conducted a case–control study of first MI after breast cancer nested among
women diagnosed with breast cancer, while enrolled in a health maintenance organisation from 1980 to 2000. We obtained
information on breast cancer treatment and MI risk factors through medical record reviews and interviews. Data were analysed using
conditional logistic regression. Of 11045 women with breast cancer, 134 met MI criteria and were matched to two MI-free control
subjects on year of birth and breast cancer diagnosis. After adjusting for smoking, hypertension and diabetes, tamoxifen was
unassociated with MI (odds ratio (OR)¼1.2, 95% confidence interval (CI)¼0.7–1.9). Duration, cumulative dose and recency of use
were not associated with MI. Radiation therapy was associated with MI (OR¼2.0, 95% CI¼1.1–3.5), an association that varied
slightly but not statistically significantly by tamoxifen use (radiation with tamoxifen, OR¼2.0, 95% CI¼0.9–4.4; radiation without
tamoxifen, OR¼2.9, 95% CI¼1.2–7.5). Tamoxifen treatment for breast cancer does not appear to increase or decrease MI risk,
although radiation therapy appears to increase MI risk.
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In 1978 the US Food and Drug Administration approved the
nonsteroidal hormone tamoxifen for treatment of advanced
postmenopausal breast cancer. Tamoxifen subsequently was
shown to reduce the risk of contralateral and recurrent breast
cancer, and to extend survival in women with all stages of breast
cancer. (Fisher et al, 1998; Early Breast Cancer Trialists’
Collaborative Group, 2005) In addition, tamoxifen halves the risk
of breast cancer in women who are aged 35–59 years with a Gail
Model (Gail et al, 1989) predicted 5-year breast cancer risk of
1.66% or greater, are aged 60 years and older or have lobular
carcinoma in situ (Fisher et al, 1998).
Tamoxifen may have added benefit due to a cardioprotective
effect. Tamoxifen appears to lower serum lipid levels in
postmenopausal women with breast cancer (Love et al, 1994;
Thangaraju et al, 1994) and has been associated with a pattern of
inflammatory markers suggesting reduced cardiovascular disease
risk (Cushman et al, 2001). In treatment trials, tamoxifen has been
associated with reduced cardiovascular disease events, but these
results have been of borderline or no statistical significance when
considering only myocardial infarction (MI) (Rutqvist and
Mattsson, 1993; McDonald et al, 1995). Tamoxifen was associated
with a reduction in deaths due to MI in one trial (McDonald and
Stewart, 1991), but was not statistically significantly associated
with deaths due to cardiovascular disease in a systematic overview
of 55 treatment trials, which enrolled 37000 women (Early Breast
Cancer Trialists’ Collaborative Group, 2005). Tamoxifen appeared
to have no impact on cardiovascular morbidity or mortality in two
prevention trials (Reis et al, 2001; Cuzick et al, 2002). Evaluating
the association of tamoxifen with MI is challenging due to the
limited number of events and deaths occurring in individual trials
as well as complexities in accurately identifying MI and controlling
for known MI risk factors.
To assess the impact of tamoxifen treatment for breast cancer on
MI risk, we conducted a case–control study nested among female
Los Angeles County residents enrolled in a large health
maintenance organisation when diagnosed with breast cancer.
Our aims were to determine whether tamoxifen treatment for
breast cancer affects MI risk, to quantify any tamoxifen effects in
terms of duration, cumulative dose and recency of use, and to
determine how known MI risk factors impact any tamoxifen
effects.
MATERIALS AND METHODS
Subjects
We conducted a case–control study of MI after breast cancer
nested within a cohort of female Los Angeles County residents who
were diagnosed with invasive breast cancer while members of a
large health maintenance organisation (Kaiser Permanente South-
ern California, KPSC). The study was approved by the Institutional
Review Boards for the Protection of Human Subjects at KPSC and
the University of Southern California, in accord with assurances
filed with and approved by the US Department of Health and
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sHuman Services. Subjects provided verbal consent prior to their
telephone interview.
Located at the University of Southern California Keck School of
Medicine, the Los Angeles County Cancer Surveillance Program
identified all women with first invasive breast cancer diagnosed at
KPSC between 1 January 1980 and 1 July 2000. We linked records
of these women with automated KPSC hospitalisation data from 1
January 1980 to 30 April 2001 to identify women who had possible
MI after their breast cancer diagnoses. We also identified women
with MI as their underlying cause of death by linking the breast
cancer patient records to cancer registry follow-up data and
California mortality files. Any breast cancer patient with one of the
following codes as a hospitalisation discharge diagnosis or cause of
death was considered a potential MI case: International Classifica-
tion of Diseases 9th Revision (ICD-9) 410.x or ICD-10 I21 or I22.
Case patients were KPSC members throughout the at-risk period
between their breast cancer and MI diagnoses. Patients with
another cancer diagnosis (other than second primary breast
cancer, cervical cancer in situ or basal or squamous cell skin
cancer) or thromboembolic disease (stroke, venous thromboem-
bolism or pulmonary embolism) occurring before their MI were
excluded because their prior condition may have impacted their
breast cancer treatment. Case patients with MI as a cause of death
were assumed to have died of MI. To confirm MI identified from
hospitalisation data, we used the presence or absence of chest pain,
cardiac enzyme test results and electrocardiograms to classify
cases as definite, probable, suspected or not acute MI following the
criteria developed by the American Heart Association Council on
Epidemiology (Gillum et al, 1984). Definite and probable MI
cases were included in the study; per the criteria, these cases had
either cardiac pain and abnormal enzyme test results or
electrocardiograms determined to meet the criteria by the
Minnesota ECG Coding Center at the University of Minnesota
(http://www.epi.umn.edu/research/ecg.shtm). Myocardial infarc-
tion determinations were made blinded to the tamoxifen treatment
status of the patient. Two groups of case patients were identified:
women with their first incident MI after their breast cancer
diagnoses and women who had MI before and after their breast
cancer diagnoses.
Two control subjects were matched to each eligible case patient
with their first MI after their breast cancer diagnosis. Control
subjects were selected at random from breast cancer patients born
within 3 years and diagnosed with breast cancer within a year as
their matched case patient. In addition, control subjects had to be
alive and KPSC members during their at-risk periods. Each control
subject’s at-risk period began with her date of breast cancer
diagnosis and extended for the duration of her matched case
patient’s at-risk period. The end of the at-risk period defined the
reference date, the time point when data collection ended for
control subjects. Like case patients, a control subject was excluded
if before her breast cancer or during her at-risk period she had
another cancer diagnosis (other than second primary breast
cancer, cervical cancer in situ or basal or squamous cell skin
cancer). In addition, each control subject could not have pre-
breast cancer evidence of thromboembolic disease (stroke, venous
thromboembolism or pulmonary embolism). Any control subject
with evidence of MI or other thromboembolic disease after her
breast cancer diagnosis was eligible to serve as a control subject up
to the day before her thromboembolic event. We confirmed the
eligibility of each control subject by reviewing medical records. If a
control subject became ineligible, another control was selected
randomly until at least two control subjects were matched to each
case patient. When fewer than two control subjects were matched
to a case patient, we identified additional control subjects by first
relaxing the matching criterion for year of birth to within 5 years
and, if necessary, relaxed the criterion of the year of diagnosis to
within 2 years. Expanded criteria were used to identify control
subjects for two case patients. Despite relaxing the matching
criteria, we were able to identify only one eligible control subject
for each of six case patients.
Data collection
Details of all breast cancer treatments (surgery, chemotherapy,
radiation and hormonal therapy) received during the at-risk
period were abstracted from medical records. In addition, we
obtained information on breast tumour characteristics, oral
contraceptive and hormone replacement therapy use, height and
weight, and histories of hypertension, diabetes and hypercholes-
terolemia. Women were classified according to whether they had
ever smoked or used oral contraceptives or menopausal hormone
therapy, as we were unable to collect detailed information on
duration of use and cumulative dose.
We attempted telephone interviews with study subjects to obtain
additional information on breast cancer therapies, smoking and
medical history. Next-of-kin were interviewed when subjects were
deceased or unable to respond. Interviews were conducted for 96
case patients and 194 control subjects; of these interviews, next-of-
kin responded on behalf of 61 case patients and 47 control
subjects. Interviews could not be conducted for 38 case patients
and 68 control subjects for these reasons: subject or next-of-kin
refusal (23 cases, 45 controls); unable to locate subject or next-of-
kin (14 cases, 14 controls); and physician denied permission to
contact (one case, nine controls).
We compiled medical record and interview data into a single
analytic database, using interview data only when medical record
data were missing for a particular factor. We created two
categories of recency of tamoxifen use at MI diagnosis (o1 year
and X1 year) and two categories of duration of tamoxifen use
(o24 months and X24 months).
Statistical analyses
We compared case patients with first MI after breast cancer to case
patients with recurrent MI after breast cancer using w
2 tests. We
compared case patients with first MI after breast cancer to their
individually matched control subjects using univariate and multi-
variate conditional logistic regression methods. Univariate and
multivariate odds ratios (OR) were estimated and 95% confidence
intervals (CI) were calculated (Breslow and Day, 1980). In all
categorical analyses, women with missing information were
included in a separate category. All multivariate analyses included
categorical items for smoking (never, ever and unknown); history
of hypertension (no, yes but no medication and yes received
medication); history of diabetes (no, yes but no medication and
yes received medication); and a combined tamoxifen and radiation
therapy variable (not treated with either, received radiation
therapy only, received tamoxifen only, or received both). In
multivariate analyses assessing the impact of tamoxifen duration,
cumulative dose and recency of use, the combined tamoxifen–
radiation therapy item was replaced by items for tamoxifen
duration, cumulative dose or recency of use plus an item for
radiation therapy (yes/no). Similarly, in multivariate analyses
assessing the impact of radiation therapy cumulative dose or side
or site irradiated, the combined item was replaced by items for
radiation therapy cumulative dose or side or site irradiated plus an
item for tamoxifen (yes/no). All statistical tests were two-sided
with a P-value of 0.05 considered statistically significant. All
analyses were completed using SAS Version 8.02 (SAS Institute,
Cary, NC, USA).
RESULTS
A total of 11045 female Los Angeles County residents were
diagnosed with their first invasive breast cancer at KPSC between 1
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sJanuary 1980 and 1 July 2000 (Figure 1). Among these women, 303
had possible MI based on hospitalisation and mortality records,
with 134 who met first incident MI eligibility criteria. An
additional 35 women had MI both before and after their breast
cancer diagnoses. The remaining 134 women were ineligible: 28
had thromboembolic disease other than MI before their breast
cancer diagnoses; 96 did not meet MI diagnostic criteria or had
insufficient information for evaluation; three had insufficient
tamoxifen use information; and seven had a second cancer
diagnosed during their at-risk period. Of the 10742 women
without evidence of an MI after their breast cancer diagnosis, 317
were individually matched on year of birth, year of breast cancer
diagnosis and at-risk period to case patient with first incident MI.
We excluded 55 of these potential control subjects: 23 had
thromboembolic disease other than MI before their breast cancer
diagnoses; nine had insufficient tamoxifen use information; 18 had
a second cancer diagnosed during their at-risk period; and five
were not a true match. Thus, 262 control subjects were matched to
134 case patients.
The mean age of subjects at breast cancer diagnosis was 66.8
years (standard deviation 10.6) and mean at-risk period was 6.2
years (standard deviation 4.9); age and at-risk period distributions
are shown in Table 1. Myocardial infarction occurred 1–9 years
after breast cancer in 57.5% of the case patients, with 16.4%
occurring within 1 year and 26.1% more than 10 years later. Over
half (53.7%) of MI were classified as definite; 40 (29.9%) of case
patients were identified from death certificates.
Nearly 75% of case patients and control subjects were white
(Table 2). Body mass index, hypercholesterolemia and use of oral
contraceptives and hormone replacement therapy were not
associated with first MI after breast cancer. Myocardial infarction
was associated with histories of hypertension and diabetes
requiring medication (OR¼2.1, 95% CI 1.3–3.4 and OR¼3.0,
95% CI 1.6–5.6 respectively). Over 60% of case patients and
11, 045 breast cancer diagnoses 
1/1/1980 to 7/1/2000 among 
Los Angeles County resident 
members of a large HMO 
303 women hospitalised for or 
deceased due to myocardial 
infarction:  ICD-9 410.x or  
ICD-10 I21 and I22 
(potential cases) 
 317 randomly sampled women 
without evidence of myocardial 
infarction after their breast cancer 
diagnoses; matched to cases 
patients on year of birth and breast 
cancer diagnosis, and at-risk period  
(potential controls) 
55 ineligible  
• 23 other thromboembolic 
diseases 
• Nine insufficient information to 
classify tamoxifen use 
• 18 diagnosed with another 
cancer 
• Five not true match to case 
169 cases 
134 ineligible  
• 28 other thromboembolic 
diseases before breast 
cancer diagnoses 
• 75 did not meet myocardial 
infarction eligibility criteria 
• 21 insufficient information to 
evaluate possible 
myocardial infarction 
• Three insufficient information 
to classify tamoxifen use 
• Seven diagnosed with 
another cancer 
134 case patients 
with first 
myocardial  
infarctions after 
breast cancer 
diagnoses 
262 matched to 
case patients with 
first myocardial 
infarctions after 
breast cancer 
diagnoses
35 case patients 
with myocardial  
infarctions before 
and after breast 
cancer diagnoses 
Figure 1 Subject eligibility determination.
Table 1 Subject characteristics
Case patients with
first MI after breast
cancer (n¼134)
Controls without
MI (n¼262)
Characteristic N (%) N (%)
Age at breast cancer diagnosis (years)
o50 10 (7.5) 16 (6.1)
50–59 23 (17.2) 48 (18.3)
60–69 46 (34.3) 91 (34.7)
70–79 42 (31.3) 86 (32.8)
X80 13 (9.7) 21 (8.0)
Year of breast cancer diagnosis
1980–1984 40 (29.9) 75 (28.6)
1985–1989 49 (36.6) 96 (36.6)
1990–1994 27 (20.2) 59 (22.5)
1995–1998 18 (13.4) 32 (12.2)
Years between initial breast cancer and MI diagnoses
a
o1 22 (16.4) 42 (16.0)
1–3 34 (25.4) 69 (26.3)
4–6 26 (19.4) 52 (19.9)
7–9 17 (12.7) 32 (12.2)
X10 35 (26.1) 67 (25.6)
MI classification
Definite 72 (53.7) Not applicable
Probable 22 (16.4)
Immediate fatality
b 40 (29.9)
aAs control subjects had no MI, data are from the reference date that marks the end
of control subjects’ at-risk period, which began at control subjects’ dates of breast
cancer diagnosis and extended for the duration of the matched case patients’ time
from breast cancer to MI diagnoses.
bCases identified from death certificate only; no
diagnostic work-up to permit classification.
MI risk and tamoxifen
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tumour characteristic was associated with MI (Table 3).
About half of case patients and control subjects received
tamoxifen therapy. In a multivariate model controlling for
radiation therapy, smoking and histories of hypertension and
diabetes, tamoxifen was not associated with first incident MI after
breast cancer (OR¼1.2, 95% CI 0.7–1.9, Table 3). Myocardial
infarction was not associated with duration, cumulative dose or
recency of tamoxifen use at MI (data not shown for dose and
recency). Radiation therapy was associated with MI in the
multivariate model (OR¼2.0, 95% CI 1.1–3.5). The association
of radiation therapy with MI did not vary by cumulative dose, left
vs right side irradiated, or breast/chest vs other site irradiated
(data not shown). When considered together in the multivariate
model, the association of radiation therapy with MI was somewhat
lower in tamoxifen users than in nonusers (OR¼2.0, 95% CI
0.9–4.4 and OR¼2.9, 95% CI 1.2–7.5, respectively) although this
difference was not statistically significant (P¼0.49). The combined
effect of radiation therapy and tamoxifen on MI was consistent
across levels of tamoxifen duration, cumulative dose and recency,
although small sample sizes limit interpretation (data not shown
for dose and recency). Chemotherapy was not associated with MI.
These results did not change when stage at diagnosis was included
in the model and did not vary by time between breast cancer
diagnosis and MI. The association of smoking with MI was
strengthened when cases identified through mortality records were
removed from the analysis. There were no further changes in
associations when models were restricted to case patients with
definite MI (data not shown).
Case patients with MI before and after their breast cancer
diagnoses were similar in age to case patients with their first MI
after their breast cancer diagnoses (Table 4). Case patients with MI
before and after their breast cancer diagnoses were more likely to
be white and experienced their post-breast cancer MI closer in
time to their breast cancer diagnoses than case patients with their
first MI after their breast cancer diagnoses. Compared to case
patients with first MI after their breast cancer diagnoses, case
patients with MI before and after their breast cancer diagnoses
were more likely to have been treated for hypertension and
diabetes and to have ever smoked. Use of adjuvant tamoxifen and
radiation therapy was similar in the two case patient groups.
DISCUSSION
We found that adjuvant tamoxifen therapy was not associated with
first MI after breast cancer, regardless of duration, cumulative dose
or recency of use. Myocardial infarction was associated with
radiation therapy and was more common in smokers and women
with histories of medication-treated hypertension or diabetes. We
did not detect any association between MI and radiation therapy
cumulative dose or side or site irradiated. The association of
radiation therapy with MI appeared reduced slightly among
tamoxifen users, but we did not have sufficient statistical power
to demonstrate that the effect differed from nonusers. These
results inform clinical decision-making and are pertinent to
weighing the relative risks and benefits of tamoxifen vs other
treatments like aromatase inhibitors.
Despite evidence that tamoxifen lowers serum lipid levels in
postmenopausal women with breast cancer (Love et al, 1994;
Thangaraju et al, 1994) and is associated with a pattern of
inflammatory markers suggesting reduced cardiovascular disease
risk (Cushman et al, 2001), tamoxifen trials have not demonstrated a
consistent, statistically significant reduction in morbidity or mortality
due to MI. McDonald et al (1995) reported a hazard ratio of 1.92
(95% CI 0.99–3.73) for MI in women randomised to the control arm
relative to those randomised to the tamoxifen arm. Rutqvist and
Mattsson (1993) reported a relative hazard of 0.83 (95% CI 0.45–
1.56) for MI in tamoxifen arm patients relative to control arm
patients, and noted no differences by duration of tamoxifen therapy.
One treatment trial reported an association between tamoxifen and
reduced MI deaths (McDonald and Stewart, 1991), but a systematic
overview of 55 randomised trials (Early Breast Cancer Trialists’
Collaborative Group, 2005) failed to confirm this association.
Prevention trials have not reported an association between tamoxifen
and cardiovascular disease (Reis et al, 2001; Cuzick et al, 2002).
Using stringent MI diagnostic criteria and controlling for known MI
risk factors, our results provide no support for an association
between tamoxifen use and first MI after breast cancer.
Studies examining a possible association of radiation therapy
with MI have conflicting results. An overview of early breast cancer
radiation therapy trials reported an association with vascular
mortality in breast cancer survivors (Early Breast Cancer Trialists’
Table 2 Odds ratios (OR) and 95% confidence intervals (95% CI) of first
myocardial infarction (MI) after breast cancer diagnosis associated with
subject characteristics and medical history
Characteristics
# of cases/# of
controls
Univariate OR
(95% CI)
Multivariate
a
OR (95% CI)
Race/ethnicity
Black 19/45 0.8 (0.5–1.5) 0.6 (0.3–1.1)
White 97/191 1.0 (referent) 1.0 (referent)
Other/unknown 18/26 1.4 (0.7–2.6) 1.2 (0.6–2.5)
Body mass index at MI (kg/m
2)
b
o25 52/105 1.0 (referent) 1.0 (referent)
25–29.9 38/79 0.9 (0.6–1.6) 0.8 (0.4–1.4)
430 31/58 1.1 (0.6–1.9) 0.8 (0.4–1.5)
Unknown 13/20
Oral contraceptive use ever
No 93/201 1.0 (referent) 1.0 (referent)
Yes 25/43 1.5 (0.8–3.0) 1.5 (0.7–3.0)
Unknown 16/18
Use of oestrogen and/or hormone replacement therapy ever
No 60/105 1.0 (referent) 1.0 (referent)
Yes 69/147 0.8 (0.5–1.2) 0.9 (0.5–1.4)
Unknown 5/10
Smoking status at MI
b
Never 70/156 1.0 (referent) 1.0 (referent)
Ever 59/100 1.3 (0.8–2.0) 1.5 (0.9–2.4)
Unknown 5/6
History of hypertension
No 34/111 1.0 (referent) 1.0 (referent)
Yes, no
medication
7/28 0.8 (0.3–2.1) 0.7 (0.3–2.0)
Yes, medication 93/123 2.5 (1.5–4.0) 2.1 (1.3–3.4)
History of diabetes
No 88/217 1.0 (referent) 1.0 (referent)
Yes, no
medication
8/13 1.5 (0.6–4.2) 1.5 (0.6–4.2)
Yes, medication 38/32 3.2 (1.8–5.6) 3.0 (1.6–5.6)
History of hypercholesterolemia
No 68/150 1.0 (referent) 1.0 (referent)
Yes, no
medication
34/76 1.0 (0.6–1.8) 1.1 (0.6–2.0)
Yes, medication 32/36 2.0 (1.1–3.7) 1.4 (0.7–2.7)
aMultivariate model includes categorical items for the named characteristic, histories
of hypertension and diabetes, smoking and a combined item for tamoxifen and
radiation treatment.
bAs control subjects had no MI, data are from the reference date
that marks the end of control subjects’ at-risk period, which began at control subjects’
dates of breast cancer diagnosis and extended for the duration of the matched case
patients’ time from breast cancer to MI diagnoses.
MI risk and tamoxifen
AM Geiger et al
1617
British Journal of Cancer (2005) 92(9), 1614–1620 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sCollaborative Group, 2000). Rutqvist and Johansson (1990)
reported that radiation therapy for left-sided breast cancer given
in 1970–1980 resulted in a statistically significant higher mortality
due to MI. Paszat et al (1998) reported an association of radiation
therapy with fatal MI in women with left-sided cancer diagnosed
from 1973–1992, particularly among women under age 60 years.
Yet two studies of women treated in the 1980s reported no
association of radiation therapy with MI morbidity or mortality
(Hojris et al, 1999; Vallis et al, 2002). Study differences in length of
patient follow-up, changes in radiation therapy techniques over
time and a lack of control for other risk factors may explain the
variable findings. Right-sided radiation exposures may contribute
to increased MI risk due to scatter, or this may be a spurious
finding. The results of our study using confirmed MI and
controlling for other risk factors support the possibility that
radiation therapy is associated with increased MI risk, but cannot
confirm this association due to the majority of our patients
receiving mastectomy, leaving small numbers of patients eligible
for radiation therapy. In addition, our study was not designed to
examine associations between radiation therapy and MI, and thus
did not include an effort to estimate radiation dose to the heart;
future studies should include this approach.
For the majority of our subjects we gathered detailed informa-
tion on tamoxifen use from medical records, information not
impacted by self-report bias. Nevertheless, we were unable to
accurately classify tamoxifen use for a small proportion of study
subjects due to insufficient medical record information. In
addition, small numbers limit our ability to reach conclusions
about the relative effects of short- and long-course tamoxifen use.
While randomised controlled trials are the strongest design for
determining treatment efficacy, the application of trial results may
be limited when trial conditions differ from clinical practice
(Fletcher, 2002). In this common situation, observational studies
provide useful information for application of trial results to clinical
practice (Vijan et al, 2000). The interpretation and application of
tamoxifen treatment trial results are hampered by volunteer bias
and stringent eligibility criteria that create systematic differences
between trial participants and the population of all women with
breast cancer. In addition most tamoxifen trials have limited
ability to collect data on anything other than primary end points,
thus secondary diagnoses are not confirmed and information on
risk factors is unavailable. Owing to potential selection bias and
misclassification of exposure and outcome variables, trial-based
estimates of MI incidence after breast cancer treatment are likely
inaccurate. We conducted a population-based study in which we
were able to include women without regard to willingness to
participate in a trial and without any exclusion criteria, thus
enhancing the generalisability of our results to clinical practice. In
addition, by conducting our study within an integrated health care
system, we were able to identify and confirm MI diagnoses
Table 3 Odds ratios (OR) and 95% confidence intervals (95% CI) of first
myocardial infarction after breast cancer diagnosis associated with tumor
and treatment characteristics
Characteristics
# of cases/# of
controls
Univariate OR
(95% CI)
Multivariate
a
OR (95% CI)
Stage at diagnosis
Localised 89/183 1.0 (referent) 1.0 (referent)
Regional 38/73 1.1 (0.7–1.7) 1.0 (0.6–1.8)
Distant/unstaged 7/6 2.5 (0.8–8.0) 2.2 (0.6–7.7)
Oestrogen receptor status
Negative 20/45 1.0 (referent) 1.0 (referent)
Positive or
borderline
86/154 1.3 (0.7–2.4) 1.3 (0.6–2.6)
Not done 28/63
Progesterone receptor status
Negative 33/73 1.0 (referent) 1.0 (referent)
Positive or
borderline
61/110 1.3 (0.8–2.1) 1.1 (0.6–1.9)
Not done 40/79
Lymph nodes involved
No 75/155 1.0 (referent) 1.0 (referent)
Yes 37/71 1.1 (0.7–1.7) 1.0 (0.6–1.9)
No nodal
surgery
22/36
Tamoxifen therapy ever
b
No 65/132 1.0 (referent) 1.0 (referent)
Yes 69/130 1.1 (0.7–1.8) 1.2 (0.7–1.9)
Duration of use (months)
None 65/132 1.0 (referent) 1.0 (referent)
o24 29/47 1.5 (0.8–2.9) 1.6 (0.8–3.2)
X24 35/79 0.9 (0.5–1.5) 0.9 (0.5–1.7)
Unknown 5/4
Radiation therapy
b
No 101/223 1.0 (referent) 1.0 (referent)
Yes 33/39 1.8 (1.1–3.1) 2.0 (1.1–3.5)
Radiation cumulative dose (rads)
c
None 101/223 1.0 (referent) 1.0 (referent)
p5000 18/18 2.1 (1.04–4.4) 2.2 (1.01–4.8)
45000 14/20 1.5 (0.7–3.1) 1.7 (0.7–3.8)
Radiation side
None 101/223 1.0 (referent) 1.0 (referent)
Right 13/14 2.0 (0.9–4.8) 2.1 (0.8–5.3)
Left 20/25 1.7 (0.9–3.2) 1.9 (0.9–3.9)
Tamoxifen and radiation therapy
Neither 52/120 1.0 (referent) 1.0 (referent)
Radiation
therapy only
13/12 2.5 (1.02–5.9) 2.9 (1.2–7.5)
Tamoxifen only 49/103 1.2 (0.7–2.0) 1.3 (0.8–2.3)
Both 20/27 1.8 (0.9–3.6) 2.0 (0.9–4.4)
Tamoxifen months of use and radiation therapy
b
Neither 52/120 1.0 (referent) 1.0 (referent)
Radiation
therapy only
13/12 2.5 (1.04–6.1) 2.9 (1.1–7.5)
No radiation
therapy
Tamoxifen
o24 18/36 1.5 (0.7–3.0) 1.7 (0.8–3.7)
X24 26/64 1.0 (0.5–1.8) 1.1 (0.6–2.1)
Radiation therapy
Tamoxifen
o24 11/11 2.4 (0.9–6.4) 3.2 (1.1–9.1)
X24 9/15 1.4 (0.5–3.7) 1.4 (0.5–4.0)
Table 3 (Continued)
Characteristics
# of cases/# of
controls
Univariate OR
(95% CI)
Multivariate
a
OR (95% CI)
Tamoxifen
months unknown
5/4
Chemotherapy
No 109/218 1.0 (referent) 1.0 (referent)
Yes 25/44 1.2 (0.6–2.1) 1.2 (0.6–2.3)
aAll multivariate models include categorical items for histories of hypertension and
diabetes, smoking and a combined item for tamoxifen and radiation treatment.
bIn
multivariate model, the combined tamoxifen-radiation therapy item was replaced by
separate items. For example, the model to examine tamoxifen duration of use
included the radiation therapy (yes/no) item.
cSubjects with details unknown
removed (one case with matched controls, one control).
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MI risk factors. We likely identified all MI because KPSC has a
safe and effective system for returning members hospitalised at
non-KPSC facilities to KPSC facilities (Selevan et al, 1999). We
approximated randomisation by matching on age, year of
diagnosis and at-risk period.
To date, randomised trials have reported mixed results on the
association of MI morbidity and mortality with adjuvant tamoxifen
use. In our case–control study of MI after first invasive breast
cancer diagnosis nested among female residents of Los Angeles
County enrolled in a large health maintenance organisation, we
found no association of adjuvant tamoxifen use with first MI,
including no impact of duration, cumulative dose or recency of use.
Our results complement trial results by documenting that among a
general population of women diagnosed with breast cancer,
tamoxifen treatment does not appear to increase or decrease MI
risk, and suggest that prevention of MI should not be considered an
advantage of tamoxifen use. In addition, we identified an association
of radiation therapy and MI, an association reported in some but
not all prior studies. Consistent with Constine and Lipshultz (2004),
we believe that women with a history of radiation therapy or any
other potentially cardiotoxic therapy for breast cancer will benefit
from ongoing risk factor monitoring and lifestyle modifications to
improve cardiovascular health.
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Table 4 Comparison of case patients with first myocardial infarction (MI)
after breast cancer vs case patients with MI before and after breast cancer
Case patients
with first MI after
breast cancer
(n¼134)
Cases with MI
before and after
breast cancer
(n¼35)
Characteristic N (%) N (%) P
Year of breast cancer
diagnosis
0.18
1980–1984 40 (29.9) 5 (14.3)
1985–1989 49 (36.6) 12 (34.3)
1990–1994 27 (20.2) 11 (31.4)
1995–1998 18 (13.4) 7 (20.0)
Years between initial
breast cancer and post-
breast cancer MI
diagnosis
0.011
o1 22 (16.4) 11 (31.4)
1–3 34 (25.4) 11 (31.4)
4–6 26 (19.4) 7 (20.0)
7–9 17 (12.7) 6 (17.1)
X10 35 (26.1) 0 (0.0)
MI classification 0.62
Definite 72 (53.7) 18 (51.4)
Probable 22 (16.4) 4 (11.4)
Immediate fatality
a 40 (29.9) 13 (37.1)
Age at breast cancer
diagnosis (years)
0.13
o50 10 (7.5) 1 (2.9)
50–59 23 (17.2) 1 (2.9)
60–69 46 (34.3) 13 (37.1)
70–79 42 (31.3) 14 (40.0)
480 13 (9.7) 6 (17.1)
Race/ethnicity 0.072
Black 19 (14.2) 6 (17.1)
White 97 (72.4) 29 (82.9)
Other/unknown 18 (13.4) 0 (0.0)
Oral contraceptive use
ever
0.12
No 93 (69.4) 21 (60.0)
Yes 25 (18.7) 5 (14.3)
Unknown 16 (11.9) 9 (25.7)
Use of oestrogen and/or
hormone replacement
therapy ever
0.83
No 60 (44.8) 14 (40.0)
Yes 69 (51.5) 20 (57.1)
Unknown 5 (3.7) 1 (2.9)
Smoking status at MI 0.004
Never 70 (52.2) 9 (25.7)
Ever 59 (44.0) 21 (60.0)
Unknown 5 (3.7) 5 (14.3)
History of hypertension 0.091
No 34 (25.4) 3 (8.6)
Yes, no medication 7 (5.2) 3 (8.6)
Yes, medication 93 (69.4) 29 (82.9)
History of diabetes 0.18
No 88 (65.7) 1 (48.6)
Yes, no medication 8 (6.0) 3 (8.6)
Yes, medication 38 (28.4) 15 (42.9)
History of
hypocholesterolemia
0.82
No 68 (50.8) 16 (45.7)
Table 4 (Continued)
Case patients
with first MI after
breast cancer
(n¼134)
Cases with MI
before and after
breast cancer
(n¼35)
Characteristic N (%) N (%) P
Yes, no medication 34 (25.4) 9 (25.7)
Yes, medication 32 (23.9) 10 (28.6)
Stage at diagnosis 0.99
Localised 89 (66.4) 23 (65.7)
Regional 38 (28.4) 10 (28.6)
Distant/unstageable 7 (5.2) 2 (5.7)
Oestrogen receptor
status
0.26
Negative 20 (14.9) 2 (5.7)
Positive or
borderline
86 (64.2) 27 (77.1)
Not done 28 (20.9) 6 (17.1)
Progesterone receptor
status
0.17
Negative 33 (24.6) 5 (14.3)
Positive or
borderline
61 (45.5) 22 (62.9)
Not done 40 (29.9) 8 (22.9)
Tamoxifen and radiation
therapy
0.15
Neither 52 (38.8) 8 (22.9)
Radiation therapy
only
13 (9.7) 2 (5.7)
Tamoxifen only 49 (36.6) 20 (57.1)
Both 20 (14.9) 5 (14.3)
aCases identified from death certificate only; no diagnostic work-up to permit
classification.
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